What clinicians need to know about antioestrogen resistance in breast cancer therapy

被引：38

作者：

Milano, Amalia ^{[1
]}

Dal Lago, Lissandra ^{[1
]}

Sotiriou, Christos ^{[1
]}

Piccart, Martine ^{[1
]}

Cardoso, Fatima ^{[1
]}

机构：

[1] Inst Jules Bordet, Med Oncol & Translat Res Unit, B-1000 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2006年 / 42卷 / 16期

关键词：

breast cancer; tamoxifen-resistance; predictive marker; AIB1; HER-2; oestrogen receptor; progesterone receptor; cox-2; cyclin E; UPA/PAI-1;

D O I：

10.1016/j.ejca.2006.06.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tamoxifen is the drug most used for early breast cancer treatment in oestrogen receptor (ER) positive patients. Unfortunately, despite high ER tumour levels in a tumour, resistance to endocrine therapy, either de novo or acquired after prolonged treatment, can occur. In this review, we will try to summarise the postulated mechanisms of hormonal-resistance, namely, the role of co-regulators and the crosstalk between the HER-2, IGF-IR, Cox-2 and ER pathways. Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：2692 / 2705

页数：14

共 128 条

[91] Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action [J].

Osborne, CK ;

Wakeling, A ;

Nicholson, RI .

BRITISH JOURNAL OF CANCER, 2004, 90 (Suppl 1) :S2-S6

[92] Double-blind, Randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial [J].

Osborne, CK ;

Pippen, J ;

Jones, SE ;

Parker, LM ;

Ellis, M ;

Come, S ;

Gertler, SZ ;

May, JT ;

Burton, G ;

Dimery, I ;

Webster, A ;

Morris, C ;

Elledge, R ;

Buzdar, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3386-3395

[93] COMPARISON OF THE EFFECTS OF A PURE STEROIDAL ANTIESTROGEN WITH THOSE OF TAMOXIFEN IN A MODEL OF HUMAN BREAST-CANCER [J].

OSBORNE, CK ;

CORONADOHEINSOHN, EB ;

HILSENBECK, SG ;

MCCUE, BL ;

WAKELING, AE ;

MCCLELLAND, RA ;

MANNING, DL ;

NICHOLSON, RI .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (10) :746-750

[94] A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J].

Paik, S ;

Shak, S ;

Tang, G ;

Kim, C ;

Baker, J ;

Cronin, M ;

Baehner, FL ;

Walker, MG ;

Watson, D ;

Park, T ;

Hiller, W ;

Fisher, ER ;

Wickerham, DL ;

Bryant, J ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2817-2826

[95] Expression of Bcl-2 protein in human primary breast carcinomas and its correlation with multifocality, histopathological types and prognosis [J].

Papadimitriou, CS ;

Costopoulos, JS ;

Christoforidou, BP ;

Kotsianti, AJ ;

Karkavelas, GS ;

Hytiroglou, PM ;

Koufogiannis, DJ ;

Nenopoulou, HE .

EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) :1275-1280

[96] Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line [J].

Parisot, JP ;

Hu, XF ;

DeLuise, M ;

Zalcberg, JR .

BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) :693-700

[97] Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line [J].

Parisot, JP ;

Leeding, KS ;

Hu, XF ;

DeLuise, M ;

Zalcberg, JR ;

Bach, LA .

BREAST CANCER RESEARCH AND TREATMENT, 1999, 55 (03) :231-242

[98] Molecular portraits of human breast tumours [J].

Perou, CM ;

Sorlie, T ;

Eisen, MB ;

van de Rijn, M ;

Jeffrey, SS ;

Rees, CA ;

Pollack, JR ;

Ross, DT ;

Johnsen, H ;

Akslen, LA ;

Fluge, O ;

Pergamenschikov, A ;

Williams, C ;

Zhu, SX ;

Lonning, PE ;

Borresen-Dale, AL ;

Brown, PO ;

Botstein, D .

NATURE, 2000, 406 (6797) :747-752

[99]

PEYRAT JP, 1988, CANCER RES, V48, P6429

[100] The predictive value of HER2 in breast cancer [J].

Piccart, M ;

Lohrisch, C ;

Di Leo, A ;

Larsimont, D .

ONCOLOGY, 2001, 61 :73-82

← 4 5 6 7 8 9 10 11 12 13 →